Buscar
-
Osteopontin: A Promising Therapeutic Target in Cardiac Fibrosis
(Cells. vol. 8, n° 12, 2019-12-03)Article de revueLibre acceso -
Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression.
(Molecular and Cellular Biochemistry, 2022-03-25)Article de revueLibre acceso -
Na/H exchanger isoform 1-induced osteopontin expression facilitates cardiac hypertrophy through p90 ribosomal S6 kinase.
(Physiological Genomics. vol. 50, n° 5, pp. 332-342, 2018-05-01)Article de revueLibre acceso -
Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin-angiotensin-aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study.
(Molecular Biology Reports. vol. 49, n° 3, pp. 2321-2324, 2022-03-01)Article de revueLibre acceso -
Anti-hypertrophic effect of Na+/H+ exchanger-1 inhibition is mediated by reduced cathepsin B
(European Journal of Pharmacology. vol. 888, pp. 173420, 2020)Article de revueLibre acceso -
Na+/H+ Exchanger Isoform 1-Induced Osteopontin Expression Facilitates Cardiomyocyte Hypertrophy
(PLoS ONE. vol. 10, n° 4, pp. e0123318, 2015-04)Article de revueLibre acceso